ICU Medical

ICU Medical

ICU Medical was founded in 1984 by Dr. George Lopez, a cardiologist who developed a closed IV system to reduce catheter-related infections. The company went public in 1992 and is headquartered in San Clemente, California. Its wealth originated from operational cash flows and public equity markets rather than a single family fortune. The firm operates across two primary segments: infusion systems (including large-volume pumps and ambulatory devices) and consumables (IV sets, syringes, and custom administration sets). It acquired the Hospira infusion systems business from Pfizer for approximately $1B in 2017, adding a vast installed base and manufacturing capacity. Geographically, the company sells in over 50 countries, with key markets in the United States, Europe, and Asia. Portfolio highlights include the Plum 360 smart infusion pump and the Guardian needle-free IV systems. ICU Medical has roughly 8,000 employees globally (per public filings, 2022) and maintains R&D and manufacturing operations in the US, Mexico, and Ireland. The firm also operates a charitable foundation but does not run separate investment vehicles. In May 2024, the company reported a 9 percent revenue decline in its infusion systems segment in Q1 2024 versus the prior year, citing supply chain normalization and hospital budget constraints. The structural differentiator of ICU Medical is its dual identity as a publicly traded medical device manufacturer with a single-focus product line — infusion therapy. Unlike diversified conglomerates, the firm concentrates all engineering and regulatory resources on a single clinical workflow, which allows faster FDA approvals and deeper hospital integration, but also makes it vulnerable to hospital purchasing cycles and generic competition.